Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PREDICT THE DRUG

Financiado

Using ex vivo functional genomics as biomarker to predict the effectivity of Ven...

Using ex vivo functional genomics as biomarker to predict the effectivity of Venetoclax in patients with acute leukemias For decades, oncologists treating cancer patients desire biomarkers that predict drug sensitivity on a patient individual level; unfortunately, the challenge remains unsolved until today. As treating clinicians are unable to ident... ver más

30/06/2025

HMGU

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-26

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

HMGU

150.00K€ | Lider

Proyectos interesantes

BIO2017-85364-R PREDICCION DE VULNERABILIDADES TERAPEUTICAS EN CANCER POR ME... 242K€ Cerrado

SC-Plasticity Applying novel single-cell multiomics to elucidate leukaemia... 2M€ Cerrado

SAF2013-49056-R ANALISIS GENOMICO-FUNCIONAL DE LA RESISTENCIA A LAS TERAPIAS... 133K€ Cerrado

PID2020-115097RA-I00 USO DE LETALIDAD SINTETICA EN GENES MODIFICADORES DE LA CROM... 194K€ Cerrado

PID2021-128312OB-I00 ALTERACIONES MOLECULARES DEL CARCINOMA RENAL METASTASICO CON... 196K€ Cerrado

ONCOTRACK OncoTrack - Methods for systematic next generation oncology... 31M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 20 meses Fecha Inicio: 2023-10-26
Fecha Fin: 2025-06-30

Presupuesto del proyecto 150K€

Descripción del proyecto For decades, oncologists treating cancer patients desire biomarkers that predict drug sensitivity on a patient individual level; unfortunately, the challenge remains unsolved until today. As treating clinicians are unable to identify the patients who benefit most and despite advanced multi-omics diagnostics, the majority of cancer patients are treated according to risk groups. As a result, patients receive inactive drugs without benefit, but adverse effects and European healthcare systems lose significant resources without gain. During my ERC CoG work, we developed a completely new test principle which has the potential to bridge the gap. The group of targeted anticancer drugs causes tumor cells to die by inhibiting a single specific signalling molecule; we used the CRISPR/Cas9 mediated gene knockout to mimic the activity of such targeted drugs. In proof-of-principle work, we used patient-derived xenograft (PDX) leukemia models to show that the knockout of a target gene in vitro was able to predict which patient´s PDX model responded to treatment with the respective drug in vivo. Here, we plan to optimize our test system by studying knockout of BCL-2 to predict sensitivity to the BCL-2 targeting drug Venetoclax. The planned work harbours the potential of a major breakthrough to solve a long-standing challenge in anti-cancer treatment, namely to predict which individual patient´s tumor responds to which targeted.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores